249 related articles for article (PubMed ID: 22018955)
1. Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system.
Liu H; Zhang J; Wang S; Pang Z; Wang Z; Zhou W; Wu M
Cancer Epidemiol; 2012 Feb; 36(1):82-8. PubMed ID: 22018955
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies as potential biomarkers for nasopharyngeal carcinoma.
Tong YQ; Zhang ZJ; Liu B; Huang J; Liu H; Liu Y; Guo FJ; Zhou GH; Xie PL; Li YH; Zuo CH; Hu JY; Li GC
Proteomics; 2008 Aug; 8(15):3185-93. PubMed ID: 18654982
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies as potential biomarkers for breast cancer.
Zhong L; Ge K; Zu JC; Zhao LH; Shen WK; Wang JF; Zhang XG; Gao X; Hu W; Yen Y; Kernstine KH
Breast Cancer Res; 2008; 10(3):R40. PubMed ID: 18460216
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma.
Wang K; Xu X; Nie Y; Dai L; Wang P; Zhang J
Cancer Lett; 2009 Aug; 281(2):144-50. PubMed ID: 19304375
[TBL] [Abstract][Full Text] [Related]
5. Profiling tumor-associated autoantibodies for the detection of colon cancer.
Ran Y; Hu H; Zhou Z; Yu L; Sun L; Pan J; Liu J; Yang Z
Clin Cancer Res; 2008 May; 14(9):2696-700. PubMed ID: 18451234
[TBL] [Abstract][Full Text] [Related]
6. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma.
Chang W; Wu L; Cao F; Liu Y; Ma L; Wang M; Zhao D; Li P; Zhang Q; Tan X; Yu Y; Lou Z; Zhao J; Zhang H; Fu C; Cao G
Clin Cancer Res; 2011 Sep; 17(17):5715-24. PubMed ID: 21771877
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumor-associated antigens in human hepatocellular carcinoma by autoantibodies.
Chen X; Fu S; Chen F; Chen H; Chen Z
Oncol Rep; 2008 Oct; 20(4):979-85. PubMed ID: 18813843
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of T7 and lambda phage display systems for survey of autoantibody profiles in cancer patients.
Kalniņa Z; Siliņa K; Meistere I; Zayakin P; Rivosh A; Abols A; Leja M; Minenkova O; Schadendorf D; Linē A
J Immunol Methods; 2008 May; 334(1-2):37-50. PubMed ID: 18314130
[TBL] [Abstract][Full Text] [Related]
10. Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma.
Uemura M; Nouso K; Kobayashi Y; Tanaka H; Nakamura S; Higashi T; Ono T; Nakayama E; Hanafusa T; Shiratori Y
Cancer; 2003 May; 97(10):2474-9. PubMed ID: 12733146
[TBL] [Abstract][Full Text] [Related]
11. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer.
Zhong L; Peng X; Hidalgo GE; Doherty DE; Stromberg AJ; Hirschowitz EA
Proteomics; 2004 Apr; 4(4):1216-25. PubMed ID: 15049001
[TBL] [Abstract][Full Text] [Related]
12. Identification of HCC-22-5 tumor-associated antigen and antibody response in patients.
Zhou SF; Xie XX; Bin YH; Lan L; Chen F; Luo GR
Clin Chim Acta; 2006 Apr; 366(1-2):274-80. PubMed ID: 16356486
[TBL] [Abstract][Full Text] [Related]
13. Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma.
Nissom PM; Lo SL; Lo JC; Ong PF; Lim JW; Ou K; Liang RC; Seow TK; Chung MC
FEBS Lett; 2006 Apr; 580(9):2216-26. PubMed ID: 16574106
[TBL] [Abstract][Full Text] [Related]
14. [Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma and their significance in clinical settings].
Tong GD; Zhou DQ; He JS; Xiao CL; Liu XL; Zhou XZ; Zhang X; Xing YF; Lü P; Feitelson MA
Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):828-32. PubMed ID: 18073065
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma.
Ying X; Zhao Y; Wang JL; Zhou X; Zhao J; He CC; Guo XJ; Jin GH; Wang LJ; Zhu Q; Han SX
Oncol Rep; 2014 Oct; 32(4):1550-6. PubMed ID: 25109745
[TBL] [Abstract][Full Text] [Related]
16. A concise review of serum markers for hepatocellular cancer.
Wright LM; Kreikemeier JT; Fimmel CJ
Cancer Detect Prev; 2007; 31(1):35-44. PubMed ID: 17293059
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
18. Markers for hepatocellular carcinoma.
Wu AH; Sell S
Immunol Ser; 1990; 53():403-22. PubMed ID: 1713067
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma.
Takashima M; Kuramitsu Y; Yokoyama Y; Iizuka N; Harada T; Fujimoto M; Sakaida I; Okita K; Oka M; Nakamura K
Proteomics; 2006 Jul; 6(13):3894-900. PubMed ID: 16767786
[TBL] [Abstract][Full Text] [Related]
20. Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma.
Liu M; Varela-Ramirez A; Li J; Dai L; Aguilera RJ; Zhang JY
Oncol Rep; 2015 May; 33(5):2245-52. PubMed ID: 25779011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
